Abstract:Background Few studies have evaluated the treatment of immunoglobulin A nephropathy (IgAN) patients with nephrotic syndrome (NS) and mesangioproliferative glomerulonephritis (MPGN). The aim of this study was to compare the therapeutic effects of oral glucocorticoids (GCS) combined with intravenous cyclophosphamide (CTX) and oral GCS alone in the treatment of the MPGN-IgAN patients with NS. Methods Biopsy-proven primary IgAN patients who were aged & GE;14 years at diagnosis, had coexistent NS and MPGN and estimated glomerular filtration rate (eGFR) & GE;15 mL/min/1.73 m(2), and were treated by oral GCS combined with intravenous CTX or oral GCS alone for 6-12 months were retrospectively included. The patients in the GCS + CTX (prednisone 0.6-0.8 mg/kg/day and intravenous CTX 0.6-1.0 g monthly) or GCS (prednisone 0.8-1 mg/kg/day) group were rather matched at a 1:1 ratio on key characteristics by propensity score matching. The primary outcome was defined as either complete remission or partial remission at Month 24. The secondary outcome was a composite renal endpoint defined as a 50% decline in eGFR, doubling of serum creatinine or progression to end-stage kidney disease. Results Among the 146 IgAN patients who met the inclusion criteria, 42 patients were enrolled in the GCS + CTX group, and 42 patients were enrolled in the GCS group after propensity score matching. The clinical and histological parameters were similar between the two groups. Remission occurred more frequently in the GCS + CTX group at Month 6 (88.1% vs 52.4%, P < 0.001), Month 12 (88.1% vs 56.1%, P = 0.001) and Month 24 (85.0% vs 47.5%, P < 0.001) than in the GCS group. Moreover, subgroup analysis revealed that the higher response rate at Month 24 in the GCS + CTX group than in the GCS group was also present in different subgroups defined by sex, age, eGFR or Oxford MEST-C. Notably, we found that eGFR decreased at a lower rate in patients from the GCS + CTX group than in patients from the GCS group [eGFR slope: 0.05(-3.09, 3.67) vs -2.56 (-11.30, 0.86) mL/min/1.73 m(2)/year, P = 0.03]. Based on multivariate Cox regression analysis, GCS + CTX treatment was found to be independently associated with a decrease in risk for the composite endpoint after adjusted by the International Risk Prediction Score with race (hazard ratio = 0.17, 95% confidence interval 0.04-0.83, P = .03). There was no significant difference in adverse events (50.0% vs 42.9%, P = 0.51) or serious adverse events (7.1% vs 11.9%, P = .71) between the two groups. Conclusions Oral GCS combined with intravenous CTX is superior to GCS alone in treating MPGN-IgAN patients combined with NS. As the retrospective design and small sample size, our findings need to be validated by a prospective study. Lay Summary Immunoglobulin A nephropathy (IgAN) is the leading cause of end-stage renal disease in youth worldwide. Nephrotic syndrome (NS) is a relatively rare condition in IgAN patients, accounting for approximately 5%-15% of all IgAN patients. There are two common pathological types of IgAN with NS, minimal-change disease (MCD-IgAN) and mesangioproliferative glomerulonephritis (MPGN-IgAN). The former has been shown to respond well to glucocorticoids (GCS) and is suggested to be treated as MCD based on the 2021 KDIGO guidelines. However, the treatment strategy for the latter is not clear since there have been few studies discussing treatment options for MPGN-IgAN patients. This is the first study to compare the efficacy and safety of GCS combined with cyclophosphamide (CTX) versus GCS alone for the treatment in patients with MPGN-IgAN combined with NS. We found that the combination of GCS and CTX was more effective in reducing urinary protein than GCS alone. Furthermore, we determined that GCS combined with CTX was associated with a reduced risk of renal function deterioration in the treatment of MPGN-IgAN patients with NS. Finally, we found there was no significant difference of adverse events between the two treatment groups. In conclusion, oral GCS combined with intravenous CTX is superior to GCS alone in treating MPGN-IgAN patients combined with NS. Our study provides important evidence for the treatment of IgAN patients with NS and MPGN.

Idiopathic Nodular Glomerulosclerosis: Case Studies

Idiopathic nodular glomerulosclerosis: a case report

Clinical and Pathology Features of IgA Nephropathy with Active Tubular Interstitial Lesions

The Selective Endothelin Receptor Antagonist SC0062 in IgA Nephropathy

A Multicenter Application and Evaluation of the Oxford Classification of IgA Nephropathy in Adult Chinese Patients

Oral Glucocorticoids with Intravenous Cyclophosphamide or Oral Glucocorticoids Alone in the Treatment of IgA Nephropathy Present with Nephrotic Syndrome and Mesangioproliferative Glomerulonephritis.

[Diagnosis and Treatment of IgA Nephropathy-2023]

Clinicopathological Features and Renal Outcomes of IgA Nephropathy with Acute Tubulointerstitial Nephropathy

Natural history of immunoglobulin A nephropathy and predictive factors of prognosis: a long-term follow up of 204 cases in China.

MO233: Real-World Signs and Symptoms at Diagnosis in Patients With IGA Nephropathy

ELEVATION OF ERYTHROCYTE SEDIMENTATION RATE AND C-REACTIVE PROTEIN REFLECTS RENAL INTERSTITIAL INFLAMMATION IN DRUG-INDUCED ACUTE TUBULOINTERSTITIAL NEPHRITIS

Clinical and pathological outcomes of crescentic IgA nephropathy and Henoch-Schonlein purpura nephritis

Clinical and Pathological Features of Idiopathic Membranous Nephropathy in Young Adults and Analysis of Outcomes

Outcomes of normotensive IgA nephropathy patients with mild proteinuria who have impaired renal function

Contemporary review of IgA nephropathy

Identification and external validation of IgA nephropathy patients benefiting from immunosuppression therapy

A Cumulative Renal Survival Analysis of 495 Cases of IgA Nephropathy

#2389 Enhancing Immunoglobulin A Nephropathy Management: Insights from the IGAN-MIC Project

Clinicopathological Analysis on Glomerulonephritis Complicating with Acute Interstitial Nephritis

Elevation of erythrocyte sedimentation rate and C-reactive protein levels reflects renal interstitial inflammation in drug-induced acute tubulointerstitial nephritis

Immunoglobulin A glomerulonephropathy: A review